COX-2-PGE2-EPs in gynecological cancers
Open Access
- 3 May 2020
- journal article
- review article
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 301 (6) , 1365-1375
Abstract
Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors (COXibs) inhibit the progression of endometrial cancer, ovarian cancer and cervical cancer. However, concerning the adverse effects of NSAIDs and COXibs, it is still urgent and necessary to explore novel and specific anti-inflammation targets for potential chemoprevention. The signaling of cyclooxygenase 2-prostaglandin E2-prostaglandin E2 receptors (COX-2-PGE2-EPs) is the central inflammatory pathway involved in the gynecological carcinogenesis. Methods: Literature searches were performed to the function of COX-2-PGE2-EPs in gynecological malignancies. Results: This review provides an overview of the current knowledge of COX-2-PGE2-EPs signaling in endometrial cancer, ovarian cancer and cervical cancer. Many studies demonstrated the upregulated expression of the whole signaling pathway in gynecological malignancies and some focused on the function of COX-2 and cAMP-linked EP2/EP4 and EP3 signaling pathway in gynecological cancer. By contrast, roles of EP1 and the exact pathological mechanisms have not been completely clarified. The studies concerning EP receptors in gynecological cancers highlight the potential advantage of combining COX enzyme inhibitors with EP receptor antagonists as therapeutic agents in gynecological cancers. Conclusion: EPs represent promising anti-inflammation biomarkers for gynecological cancer and may be novel treatment targets in the near future.Keywords
Funding Information
- China Scholarship Council (CSC)
This publication has 96 references indexed in Scilit:
- Nonsteroidal anti‐inflammatory drugs and risk of ovarian cancer: systematic review and meta‐analysis of observational studiesActa Obstetricia et Gynecologica Scandinavica, 2012
- Obesity, inflammatory markers, and endometrial cancer risk: a prospective case–control studyEndocrine-Related Cancer, 2010
- mPGES-1 as a target for cancer suppressionBiochimie, 2010
- Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cellsCarcinogenesis, 2008
- Over-Expression of COX-2 Induces Human Ovarian Cancer Cells (CAOV-3) Viability, Migration and Proliferation in Association with PI3-k/Akt ActivationCancer Investigation, 2008
- Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancerBreast Cancer Research, 2007
- Seminal plasma and prostaglandin E2 up-regulate fibroblast growth factor 2 expression in endometrial adenocarcinoma cells via E-series prostanoid-2 receptor-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase pathwayHuman Reproduction, 2006
- Endothelin-1-induced Prostaglandin E2-EP2, EP4 Signaling Regulates Vascular Endothelial Growth Factor Production and Ovarian Carcinoma Cell InvasionJournal of Biological Chemistry, 2004
- Multiple Female Reproductive Failures in Cyclooxygenase 2–Deficient MiceCell, 1997
- Assignment of the Human Prostaglandin-Endoperoxide Synthase 2 (PTGS2) Gene to 1q25 by Fluorescence in Situ HybridizationGenomics, 1994